NCT01703221View on ClinicalTrials.gov

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

October 24, 2012

Primary Completion Date

April 25, 2014

Study Completion Date

April 25, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Omarigliptin

Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly

DRUG

Sitagliptin

Sitagliptin 50 mg tablet administered orally once daily

DRUG

Placebo to omarigliptin

Placebo to omarigliptin 25 mg capsule administered orally once weekly

DRUG

Placebo to sitagliptin

Placebo to sitagliptin 50 mg tablet administered orally once daily

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01703221 - Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) | Biotech Hunter | Biotech Hunter